

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

BUSINESS UPDATE

This announcement is made by Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company is pleased to announce that on 15 September 2014, Shijiazhuang No.4 Pharmaceutical Co., Ltd. (“No.4 Pharma”), a wholly owned subsidiary of the Group, has obtained the production approvals (“Approvals”) on 20 types and together 23 specifications of the small volume injections products for several therapeutic areas including cardiovascular and cerebrovascular, anti-inflammatory, trace element supplement, antipyretic, analgesic and allergy etc. All products are in glass ampule packaging format.

The obtaining by No.4 Pharma of these Approvals may bring substantial benefits to future development of the Group:

1. The product mix and therapeutic areas of the Group would be much more comprehensive. The introduction of the small volume injection products would be a good supplement to the Group’s intravenous infusion solutions in clinical usage;
2. The Group can start production and making sales once the production facilities passed the GMP certification, which brings new sources of product sales and growth potential to the Group;
3. Obtaining the Approvals of the glass ampule product types would bring benefits to the Group by substantially shortening the time required on the application for new product-type approval of the 3-in-1 plastic ampule through the way of changing the product packaging and product specification application. No.4 Pharma can apply for the new product-type approval of the 3-in-1 plastic ampule one year after obtaining the Approvals. The Group’s profitability and profit may be improved once obtaining the approvals new product-type approval of the 3-in-1 plastic ampule.

Shareholders of the Company and the potential investors are advised to exercise caution when dealing in the Shares.

By Order of the Board
Chan Ka Kit
Company Secretary

Hong Kong, 15 September 2014

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.